Substituted pyrrole-indoles

Details Substituted pyrrole-indoles Substituted pyrrole-indoles

2007-09-04

2007-09-04

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S452000, C548S465000, C548S466000, C514S412000, C514S415000

Reexamination Certificate

active

10947727

ABSTRACT:
The present invention relates generally to substituted pyrrole-indoles such as substituted pyrrole-indoles, and methods of using them.

REFERENCES:
patent: 3026325 (1962-03-01), Heinzelman et al.
patent: 3476770 (1969-11-01), Scherrer
patent: 3557142 (1971-01-01), Bell
patent: 3843683 (1974-10-01), Bell
patent: 4478819 (1984-10-01), Hercelin et al.
patent: 4736043 (1988-04-01), Michel et al.
patent: 4851406 (1989-07-01), Mertens et al.
patent: 5164372 (1992-11-01), Matsuo et al.
patent: 5420289 (1995-05-01), Musser et al.
patent: 5482960 (1996-01-01), Berryman
patent: 5502187 (1996-03-01), Ayer et al.
patent: 5541343 (1996-07-01), Himmelsbach et al.
patent: 5612360 (1997-03-01), Boyd et al.
patent: 5859044 (1999-01-01), Dow et al.
patent: 6048875 (2000-04-01), De Nanteuil et al.
patent: 6110963 (2000-08-01), Malamas
patent: 6166069 (2000-12-01), Malamas et al.
patent: 6232322 (2001-05-01), Malamas et al.
patent: 6251936 (2001-06-01), Wrobel et al.
patent: 6302837 (2001-10-01), De Nanteuil et al.
patent: 6479524 (2002-11-01), Priepke et al.
patent: 6599929 (2003-07-01), Cho et al.
patent: 6787556 (2004-09-01), Hargreaves et al.
patent: 6800645 (2004-10-01), Cox et al.
patent: 6800654 (2004-10-01), Mayer et al.
patent: 6844358 (2005-01-01), Malamas et al.
patent: 2003/0013732 (2003-01-01), Elokdah
patent: 2003/0018067 (2003-01-01), Elokdah et al.
patent: 2003/0060497 (2003-03-01), Gerlach et al.
patent: 2003/0125371 (2003-07-01), Elokdah et al.
patent: 2004/0116488 (2004-06-01), Jennings et al.
patent: 2004/0116504 (2004-06-01), Elokdah et al.
patent: 2004/0122070 (2004-06-01), Jennings
patent: 2004/0138283 (2004-07-01), Jennings et al.
patent: 2004/0204417 (2004-10-01), Perez et al.
patent: 2005/0070584 (2005-03-01), Havran et al.
patent: 2005/0070585 (2005-03-01), Elokdah et al.
patent: 2005/0070587 (2005-03-01), Elokdah et al.
patent: 2005/0070592 (2005-03-01), Gundersen
patent: 2005/0096377 (2005-05-01), Hu
patent: 2005/0113428 (2005-05-01), Gopalsamy et al.
patent: 2005/0113436 (2005-05-01), Elokdah et al.
patent: 2005/0113438 (2005-05-01), Hu et al.
patent: 2005/0113439 (2005-05-01), Hu
patent: 2005/0119296 (2005-06-01), Elokdah et al.
patent: 2005/0119326 (2005-06-01), Havran et al.
patent: 2005/0119327 (2005-06-01), Hu
patent: 2005/0215626 (2005-09-01), Havran et al.
patent: 2006/0020003 (2006-01-01), Commons et al.
patent: 2006/0052348 (2006-03-01), Commons et al.
patent: 2006/0052349 (2006-03-01), Commons et al.
patent: 2006/0052420 (2006-03-01), Commons
patent: 3147276 (1983-06-01), None
patent: 4338770 (1995-05-01), None
patent: 19543639 (1997-05-01), None
patent: 19753522 (1999-06-01), None
patent: 19963178 (2001-07-01), None
patent: 0 416 609 (1991-03-01), None
patent: 0 508 723 (1992-10-01), None
patent: 0 512 570 (1992-11-01), None
patent: 0 535 926 (1993-04-01), None
patent: 0 540 956 (1993-05-01), None
patent: 0 655 439 (1995-05-01), None
patent: 0 759 434 (1997-02-01), None
patent: 0 819 686 (1998-01-01), None
patent: 0 822 185 (1998-02-01), None
patent: 0 955 299 (1999-11-01), None
patent: 1092716 (2001-04-01), None
patent: 1092716 (2001-08-01), None
patent: 1 156 045 (2004-11-01), None
patent: 2 244 499 (1975-04-01), None
patent: 2777886 (1999-10-01), None
patent: 2 799 756 (2001-04-01), None
patent: 1 321 433 (1973-06-01), None
patent: 7-242793 (1995-09-01), None
patent: 94/13637 (1994-06-01), None
patent: 94/14434 (1994-07-01), None
patent: 94/26738 (1994-11-01), None
patent: 95/10513 (1995-04-01), None
patent: 96/06840 (1996-03-01), None
patent: 96/21656 (1996-07-01), None
patent: 96/26207 (1996-08-01), None
patent: 96/32379 (1996-10-01), None
patent: 97/09308 (1997-03-01), None
patent: 97/43260 (1997-11-01), None
patent: 97/48697 (1997-12-01), None
patent: 98/08818 (1998-03-01), None
patent: WO98/25896 (1998-06-01), None
patent: 99/28297 (1999-06-01), None
patent: 99/43651 (1999-09-01), None
patent: 99/43654 (1999-09-01), None
patent: 99/46260 (1999-09-01), None
patent: WO99/43672 (1999-09-01), None
patent: 99/50268 (1999-10-01), None
patent: 99/58519 (1999-11-01), None
patent: 99/61435 (1999-12-01), None
patent: 00/32180 (2000-06-01), None
patent: 00/35919 (2000-06-01), None
patent: 00/46197 (2000-08-01), None
patent: WO 00/46195 (2000-08-01), None
patent: 00/64876 (2000-11-01), None
patent: 00/64888 (2000-11-01), None
patent: 01/12187 (2001-02-01), None
patent: WO 02/030895 (2002-04-01), None
patent: 02/072549 (2002-09-01), None
patent: 03/000253 (2003-01-01), None
patent: 03/000649 (2003-01-01), None
patent: 03/000684 (2003-01-01), None
patent: 03/031409 (2003-04-01), None
patent: 03/068742 (2003-08-01), None
patent: 03/087087 (2003-10-01), None
patent: 2004/052854 (2004-06-01), None
U.S. Appl. No. 10/947,903, filed Sep. 23, 2004, Hu.
U.S. Appl. No. 10/947,726, filed Sep. 23, 2004, Hu et al.
U.S. Appl. No. 10/947,839, filed Sep. 23, 2004, Hu.
Krishnamurti, C. et al., “Plasminogen Activator Inhibitor: A Regulator of Ancrod-Induced Fibrin Deposition in Rabbits,”Blood, 69(3): 798-803 (Mar. 1987).
Reilly, C. et al., “Both Circulating and Clot-Bound Plasminogen Activator-1 Inhibit Endogenous Fibrinolysis in the Rat,”Arteriosclerosis and Thrombosis, 11(5): 1276-1286 (Sep./Oct. 1991).
Carmeliet, P. et al., “Plasminogen Activator Inhibitor—1 Gene-deficient Mice,”Journal of Clinical Investigation, 92: 2756-2760 (Dec. 1993).
Rocha, E. et al., “The Relationship Between Impaired Fibrinolysis and Coronary Heart Disease,”Fibrinolysis, 8: 294-303 (1994).
Aznar, J. et al., “Role of Plasminogen Activator Inhibitor Type 1 in the Pathogenesis of Coronary Artery Diseases,”Haemostasis24: 243-251 (1994).
Biemond, B. J. et al., “Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis,”Circulation, 91: 1175-1181 (1995).
Levi, M. et al., “Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Experimental Thrombosis,”Circulation85:305-312 (1992).
Nordt, T. K. et al., “Differential Regulation by Troglitazone of Plasminogen Activator Inhibitor Type 1 in Human Hepatic and Vascular Cells,”Journal of Clinical Endocrinology and Metabolism, 85(4):1563-1568 (2000).
Daci, E. et al., “Mice Lacking the Plasminogen Activator Inhibitor 1 are Protected from Trabecular Bone Loss Induced by Estrogen Deficiency,”Journal of Bone and Mineral Research, 15(8):1510-1516 (Nov. 8, 2000).
Schneiderman J. et al., “Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries,”Proc Natl Acad Sci89: 6998-7002 (Aug. 1992).
Juhan-Vague, I. et al., “Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis,”Thromb Haemost57: 67-72 (1987).
Juhan-Vague, I. et al., “PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events,”Thromb Haemost78: 565-660 (1997).
Hamsten, A. et al., “Plasminogen Activator Inhibitor in Plasma: Risk Factor For Recurrent Myocardial Infarction,”Lancet2: 3-9 (Jul. 4, 1987).
Siemens, H. J. et al., “Course of Molecular Hemostatic Markers During and After Different Surgical Procedures,”J Clin Anesthesia11: 622-629 (Dec. 1999).
Koh, K. et al., “Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal Women,”N Engl J Med336(10): 683-690 (Mar. 6, 1997).
U.S. Appl. No. 10/947,711, filed Sep. 23, 2004, Gopalsamy et al.
Aggarwal et al., “A catalytic antibody programmed for torsional activation of amide bond hydrolysis,”Chem. Eur. J., Jan. 25, 2003, 9(13), 3132-3142.
Ballantine, J. A., “The Chemistry of Bacteria,”Journal of the Chemical Society Abstracts, 1957, 2222-2227.
Charlton, Peter, “The status of plasminogen activator inhibitor-1 as a therapeutic target,”Expert Opinion On Investigational Drugs, May 1997, 6(5), 539-554.
Crandall, D. L. et al., “Characterization and comparative evaluation of a stru

Affiliated with

Also associated with

Rating

Substituted pyrrole-indoles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted pyrrole-indoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrrole-indoles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3736127